Insider Buying: Tandem Diabetes Care Inc (TNDM) Director Acquires 1,300 Shares of Stock

Share on StockTwits

Tandem Diabetes Care Inc (NASDAQ:TNDM) Director Richard P. Valencia acquired 1,300 shares of Tandem Diabetes Care stock in a transaction that occurred on Monday, November 5th. The shares were purchased at an average cost of $37.75 per share, with a total value of $49,075.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Shares of NASDAQ:TNDM opened at $37.19 on Friday. Tandem Diabetes Care Inc has a fifty-two week low of $2.14 and a fifty-two week high of $52.55.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.28). Tandem Diabetes Care had a negative return on equity of 204.32% and a negative net margin of 93.07%. The company had revenue of $46.30 million during the quarter, compared to analyst estimates of $42.71 million. During the same period in the prior year, the firm earned ($3.09) EPS. Tandem Diabetes Care’s quarterly revenue was up 71.5% on a year-over-year basis. As a group, equities research analysts anticipate that Tandem Diabetes Care Inc will post -1.35 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Cortina Asset Management LLC acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth about $6,861,000. Rhumbline Advisers acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth about $943,000. Royal Bank of Canada lifted its position in shares of Tandem Diabetes Care by 2,375,000.0% in the first quarter. Royal Bank of Canada now owns 47,502 shares of the medical device company’s stock worth $236,000 after buying an additional 47,500 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth about $203,000. Finally, Voya Investment Management LLC acquired a new stake in shares of Tandem Diabetes Care in the second quarter worth about $386,000. 62.80% of the stock is owned by institutional investors.

A number of analysts recently issued reports on TNDM shares. Oppenheimer set a $31.00 price objective on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Tuesday, July 31st. ValuEngine raised Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 4th. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Friday, October 5th. Craig Hallum set a $59.00 price objective on Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday, November 2nd. Finally, Robert W. Baird reissued a “buy” rating and set a $31.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, July 23rd. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $44.27.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Tandem Diabetes Care Inc (TNDM) Director Acquires 1,300 Shares of Stock” was published by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://weekherald.com/2018/11/10/insider-buying-tandem-diabetes-care-inc-tndm-director-acquires-1300-shares-of-stock.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: What are Institutional Investors?

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply